Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.75 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.75 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.75 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.75 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.75 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833340 | 1.00 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL833341 | 1.00 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL841634 | 1.00 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL832873 | 0.95 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL832874 | 0.95 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL3307535 | 0.95 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL841674 | 0.95 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL830619 | 0.90 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL830620 | 0.90 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL832567 | 0.86 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | disclosed |
| EP-2131840-B1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| US-20160158186-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRAIN TUMOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2016-06-09 | — | — | US | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158186-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRAIN TUMOR | DDOST, DAD1, PHGDH | HDAC1 778/4885HDAC8 569/4885HDAC3 744/4885 |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | HDAC1 163/4885HDAC8 172/4885HDAC3 558/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | HDAC1 163/4885HDAC8 172/4885HDAC3 558/4885 |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | HDAC1 394/4885HDAC8 630/4885HDAC3 2234/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | HDAC1 194/4885HDAC8 601/4885HDAC3 1873/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | HDAC1 163/4885HDAC8 172/4885HDAC3 558/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | HDAC1 163/4885HDAC8 172/4885HDAC3 558/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | HDAC1 47/4885HDAC8 7/4885HDAC3 29/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | HDAC1 589/4885HDAC8 58/4885HDAC3 757/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | HDAC1 778/4885HDAC8 569/4885HDAC3 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.